Spectrum Pharmaceuticals, Inc. (SPPI): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPPI Stock Price Chart Interactive Chart >
SPPI Price/Volume Stats
|Current price||$0.44||52-week high||$2.45|
|Prev. close||$0.43||52-week low||$0.41|
|Day high||$0.45||Avg. volume||3,897,523|
|50-day MA||$0.99||Dividend yield||N/A|
|200-day MA||$0.94||Market Cap||82.59M|
Spectrum Pharmaceuticals, Inc. (SPPI) Company Bio
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. The company was founded in 1987 and is based in Henderson, Nevada.
Most Popular Stories View All
SPPI Latest News Stream
|Loading, please wait...|
SPPI Latest Social Stream
View Full SPPI Social Stream
Latest SPPI News From Around the Web
Below are the latest news stories about SPECTRUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SPPI as an investment opportunity.
The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Spectrum Pharmaceuticals (SPPI - Research Report), with a price target of $1.50. The company's shares closed yesterday at $0.63.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -28.8% and a 20.34% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spectrum Pharmaceuticals with a $4.83 average price target, which is a 661.47% upside from current levels.
We're breaking down the biggest pre-market stock movers for Friday morning alongside the news that traders need to know about!
Yesterday, the FDA's Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) poziotinib's (pozi) risk/benefit ratio and concluded that pozi's benefits do not outweigh the risks for the treatment of HER2 exon 20 insertion mutations. Meanwhile, with a newly approved commercial product Rolvedon launching into the $2.3 billion G-CSF space, JMP Securities believes that Spectrum shares still represent a unique investment opportunity with a 34% potent
Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) entered into a five-year debt financing agreement with SLR Capital Partners for a term loan facility of up to $65 million. The company believes this transaction, combined with Spectrum's existing cash balance of $68 million as of June 30, provides sufficient capital to optimize the commercial launch of Rolvedon (eflapegrastim-xnst) injection and fund Spectrum's operations through 2024. The first was a $30 million loan drawn upon closing. The remaining
SPPI Price Returns
Continue Researching SPPIWant to do more research on Spectrum Pharmaceuticals Inc's stock and its price? Try the links below:
Spectrum Pharmaceuticals Inc (SPPI) Stock Price | Nasdaq
Spectrum Pharmaceuticals Inc (SPPI) Stock Quote, History and News - Yahoo Finance
Spectrum Pharmaceuticals Inc (SPPI) Stock Price and Basic Information | MarketWatch